Insider Selling: Clene (NASDAQ:CLNN) Major Shareholder Sells $49,587.20 in Stock

Posted by Defense World Staff on Apr 20th, 2026

Clene Inc. (NASDAQ:CLNN – Get Free Report) major shareholder Chidozie Ugwumba sold 7,748 shares of the stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $6.40, for a total value of $49,587.20. Following the completion of the sale, the insider owned 387,769 shares in the company, valued at $2,481,721.60. This trade represents a 1.96% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

On Friday, April 17th, Chidozie Ugwumba sold 25,040 shares of Clene stock. The stock was sold at an average price of $6.43, for a total value of $161,007.20.
On Wednesday, April 15th, Chidozie Ugwumba sold 6,374 shares of Clene stock. The stock was sold at an average price of $6.48, for a total value of $41,303.52.
On Thursday, April 2nd, Chidozie Ugwumba sold 24,925 shares of Clene stock. The shares were sold at an average price of $4.81, for a total value of $119,889.25.
On Wednesday, April 1st, Chidozie Ugwumba sold 4,278 shares of Clene stock. The shares were sold at an average price of $4.97, for a total value of $21,261.66.
On Tuesday, February 3rd, Chidozie Ugwumba sold 5,559 shares of Clene stock. The shares were sold at an average price of $4.10, for a total value of $22,791.90.
On Monday, February 2nd, Chidozie Ugwumba sold 3,800 shares of Clene stock. The shares were sold at an average price of $4.04, for a total value of $15,352.00.
On Friday, January 30th, Chidozie Ugwumba sold 5,686 shares of Clene stock. The shares were sold at an average price of $4.13, for a total value of $23,483.18.
On Thursday, January 29th, Chidozie Ugwumba sold 15,284 shares of Clene stock. The shares were sold at an average price of $4.32, for a total value of $66,026.88.
On Wednesday, January 28th, Chidozie Ugwumba sold 8,717 shares of Clene stock. The shares were sold at an average price of $4.91, for a total value of $42,800.47.
On Tuesday, January 27th, Chidozie Ugwumba sold 4,139 shares of Clene stock. The shares were sold at an average price of $5.08, for a total value of $21,026.12.

Clene Price Performance

CLNN opened at $6.31 on Monday. The stock has a market cap of $74.33 million, a PE ratio of -2.43 and a beta of 0.62. Clene Inc. has a 52 week low of $2.28 and a 52 week high of $13.50. The business’s fifty day simple moving average is $5.36 and its 200 day simple moving average is $6.66.

Clene (NASDAQ:CLNN – Get Free Report) last released its earnings results on Thursday, March 12th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.14). The company had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.03 million. As a group, equities analysts anticipate that Clene Inc. will post -5.19 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of CLNN. SymBiosis Capital Partners LLC bought a new position in shares of Clene during the fourth quarter valued at about $4,523,000. Scoggin Management LP grew its stake in shares of Clene by 75.1% during the third quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock valued at $1,506,000 after buying an additional 107,250 shares during the last quarter. Ensign Peak Advisors Inc grew its stake in shares of Clene by 668.6% during the fourth quarter. Ensign Peak Advisors Inc now owns 114,361 shares of the company’s stock valued at $671,000 after buying an additional 99,481 shares during the last quarter. PEAK6 LLC bought a new position in shares of Clene during the fourth quarter valued at about $294,000. Finally, State Street Corp grew its stake in shares of Clene by 138.4% during the fourth quarter. State Street Corp now owns 29,801 shares of the company’s stock valued at $175,000 after buying an additional 17,300 shares during the last quarter. 23.28% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on CLNN shares. Canaccord Genuity Group reissued a “buy” rating and issued a $48.00 target price on shares of Clene in a research note on Friday, March 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Clene in a research note on Friday, January 9th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $23.00 price objective on shares of Clene in a research note on Thursday, March 12th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Clene has an average rating of “Moderate Buy” and an average price target of $33.00.

Get Our Latest Report on CLNN

About Clene

(Get Free Report)

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).